CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
Last trade$0.6145
Day change+$0.0015 (+0.24%)
Day range$0.59 – $0.676
Volume318,671
Market cap$17M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$17.38M
Price / earnings
—
Price / book
1.26×
Price / sales
0.29×
EV / sales
0.29×
EV / EBITDA
-0.36×
Profitability
Earnings per share
-$1.87
Return on assets
-60.79%
Return on equity
-385.45%
Dividend yield
0%
Liquidity and leverage
Debt / equity
4.24×
Current ratio
6.8×
Quick ratio
5.71×
Cash ratio
4.7×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$42.05M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CVRX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$13.83M
$15.71M
$14.77M
$16.02M
$14.69M
$13.59M
$12.35M
$15.34M
Cost of revenue
$1.83M
$1.98M
$1.89M
$2.2M
$1.94M
$2.14M
$2.04M
$2.57M
Gross profit
$12M
$13.72M
$12.88M
$13.83M
$12.75M
$11.45M
$10.31M
$12.77M
Selling, general and administrative
$22.39M
$23.62M
$21.96M
$22.01M
$21.88M
$23.36M
$21.23M
$20.24M
Research and development
$2.66M
$3.13M
$3.08M
$3M
$3.15M
$2.47M
$2.52M
$2.81M
Total operating expenses
$25.04M
$26.75M
$25.04M
$25.01M
$25.02M
$25.83M
$23.75M
$23.05M
Operating income
-$13.05M
-$13.02M
-$12.16M
-$11.18M
-$12.27M
-$14.38M
-$13.44M
-$10.27M
Interest expense
-$1.61M
-$1.58M
-$1.55M
-$1.42M
-$1.48M
-$1.47M
-$1.46M
-$1.52M
Income before taxes
-$14.16M
-$14.04M
-$13.12M
-$11.94M
-$12.87M
-$14.74M
-$13.77M
-$10.72M
Income taxes
-$1K
$3K
$1K
-$7K
-$3K
-$3K
-$5K
-$71K
Net income
-$14.16M
-$14.04M
-$13.12M
-$11.93M
-$12.87M
-$14.74M
-$13.77M
-$10.65M
Net income attributable to common shareholders
-$14.16M
-$14.04M
-$13.12M
-$11.93M
-$12.87M
-$14.74M
-$13.77M
-$10.65M
EBITDA
-$12.83M
-$12.81M
-$11.96M
-$11M
-$12.07M
-$14.18M
-$13.25M
-$10.1M
Basic earnings per share
-$0.52
-$0.53
-$0.50
-$0.46
-$0.49
-$0.57
-$0.53
-$0.43
Diluted earnings per share
-$0.52
-$0.53
-$0.50
-$0.46
-$0.49
-$0.57
-$0.53
-$0.43
Recent news
Company coverage with links to the original publishers.
Rosen Law Firm has filed a class action lawsuit against CVRx, Inc. on behalf of investors who purchased common stock between July 25, 2023 and August 6, 2026. The lawsuit alleges that CVRx made materially false and misleading statements regarding revenue growth, sales practices, regulatory compliance, and reimbursement strategy. Specifically, the company allegedly engaged in improper marketing of Barostim, kickbacks, and false information to government health insurance programs, exposing it to liability under the false Claims Act and Anti-Kickback Statute. The deadline to serve as lead plaintiff is January 8, 2027.
A class action lawsuit has been filed against CVRx, Inc. alleging the company engaged in illegal sales practices, including improper marketing of Barostim, kickbacks, and false information to government health insurance programs. The lawsuit claims CVRx's revenues were partially derived from unlawful conduct and that the company made materially false statements regarding revenue, growth, compliance, and internal controls. The lead plaintiff deadline is January 8, 2027.
Rosen Law Firm has filed a securities class action lawsuit on behalf of CVRx, Inc. shareholders who purchased shares between July 25, 2023 and August 6, 2026. The lawsuit alleges that CVRx made false and misleading statements regarding revenue growth, sales practices, regulatory compliance, and sales force productivity. Specifically, the firm claims CVRx generated revenue through improper sales practices, including inappropriate marketing of Barostim, bribery, and false information provided to government health insurance programs. The deadline to serve as lead plaintiff is January 8, 2027.
A class action lawsuit has been filed against CVRx, Inc. alleging the company made false and misleading statements regarding its revenue and compliance practices. The complaint claims CVRx engaged in illegal sales practices including improper marketing of Barostim, kickbacks, and false information to government health insurance programs in violation of the false Claims Act and Anti-Kickback Statute. Investors who purchased CVRx securities between July 25, 2023 and August 6, 2026 may be eligible to recover losses, with a lead plaintiff deadline of January 8, 2027.
CVRx, Inc. faces a class action lawsuit alleging the medical device company misled investors about illegal sales practices, including improper marketing of Barostim, kickbacks, and false claims to government health insurance programs in violation of the false Claims Act and Anti-Kickback Statute. The company's stock dropped 60% on August 6, 2026, following disclosure of a Department of Justice civil investigative demand and weak sales force productivity. Investors who purchased CVRx stock between July 25, 2023 and August 6, 2026 may be eligible to participate in the lawsuit.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.